Company: TELO
Filing Date: 2025-10-20
Form Type: 8-K
Source: 0001493152-25-018634
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-10-20
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item
1.01. Entry into a Material Definitive Agreement

Telomir
Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value
Growth

Unifying
global IP rights and enabling up to $5 million in potential shareholder contributions, the agreement strengthens Telomir’s foundation
for partnerships, licensing, and long-term value creation

On
October 17, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) (“ Telomir” or the “ Company”) entered into a binding
Letter of Intent (the “ LOI”) with TELI Pharmaceuticals, Inc. (“ TELI”) to acquire all of the outstanding shares
of TELI through a stock-for-stock exchange (the “ Transaction”). The Transaction will consolidate worldwide intellectual property
and development rights to the Company’s lead investigational candidate, Telomir-1, an oral epigenetic therapy in preclinical development
for cancer, aging, and age-related diseases.

Under
the LOI, each outstanding share of TELI common stock will be exchanged for shares of the Company’s common stock, with the exchange
ratio to be determined by an independent third-party valuation based on the relative values of Telomir and TELI. Certain TELI shareholders
have also agreed to provide a $5 million cash contribution to Telomir Pharmaceuticals in support of the Transaction and future development
activities, structured as follows: $1 million at closing, $2 million upon FDA acceptance of an Investigational New Drug (IND) application
for Telomir-1, and $2 million upon initiation of a Phase 1/2 study. Shares corresponding to the $4 million in milestone contributions
will be allocated at closing but will not be issued until the respective payments are received. The closing of the Transaction is not
contingent upon receipt of the milestone funds.

The
LOI provides for a six-month lockup period on the Telomir shares to be issued to TELI shareholders and includes customary provisions
regarding confidentiality, exclusivity, and good-faith negotiation of definitive agreements. Completion of the Transaction is subject
to mutually satisfactory due diligence, final board and stockholder approvals, regulatory clearances, and execution of definitive documentation.

The
Transaction is intended to align U. S. and ex-U. S. rights to Telomir-1 within a single public company structure, thereby